Reading view
Context matching is not reasoning when performing generalized clinical evaluation of generative language models
npj Digital Medicine, Published online: 27 December 2025; doi:10.1038/s41746-025-02253-2
Context matching is not reasoning when performing generalized clinical evaluation of generative language modelsA novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domains
npj Digital Medicine, Published online: 26 December 2025; doi:10.1038/s41746-025-02277-8
A novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domainsComparison of liquid biopsy-based technologies for cancer screening
Crit Rev Clin Lab Sci. 2025 Dec 27:1-12. doi: 10.1080/10408363.2025.2606357. Online ahead of print.
ABSTRACT
Circulating plasma DNA has found important applications in diverse medical fields, including prenatal testing, transplantation, and especially cancer. Many companies have developed products for detecting minimal residual disease, selecting or monitoring therapy, assessing prognosis, and confirming diagnosis. One major application is in screening asymptomatic individuals for the presence of cancer. Screening may facilitate better clinical outcomes through earlier interventions. Collectively, these technologies are widely known as "liquid biopsies". After the extraction of free DNA from the circulation, it is analyzed by various molecular techniques to explore differences between DNA originating from normal cells and cancer cells. Circulating plasma DNA originating from tumors (ctDNA) is expected to harbor the same molecular changes as tumor tissue itself. Thus, ctDNA is considered a surrogate of cancer tissue, but without the need to perform invasive biopsies to obtain it. Many new diagnostic companies have taken advantage of this new biomarker and developed technologies for screening for one or multiple cancers. We previously estimated the amount of ctDNA in circulation, which is admixed with DNA originating from normal cells. We concluded that since only a small fraction of the whole plasma (3 liters) is used for testing (3 to 4 mL), it is possible that the retrieved ctDNA may not be enough for cancer diagnosis in all patients. This problem is more acute with small tumors. Here, we mention some companies in the "liquid biopsy" arena and analyze their clinical data to establish if their tests are close to entering the clinic. We conclude from this analysis that current data do not support the use of these technologies for population screening due to many false negative and false positive results.
PMID:41454842 | DOI:10.1080/10408363.2025.2606357
The Principle of Proportional Duty: A Knowledge-Duty Framework for Ethical Equilibrium in Human and Artificial Systems
Machine learning-based predictions of healthcare contacts following emergency hospitalisation using electronic health records
npj Digital Medicine, Published online: 17 December 2025; doi:10.1038/s41746-025-02138-4
Machine learning-based predictions of healthcare contacts following emergency hospitalisation using electronic health recordsData-Chain Backdoor: Do You Trust Diffusion Models as Generative Data Supplier?
AI4EOSC: a Federated Cloud Platform for Artificial Intelligence in Scientific Research
XTC, A Research Platform for Optimizing AI Workload Operators
Multi-Modality Collaborative Learning for Sentiment Analysis
Towards Practical Alzheimer's Disease Diagnosis: A Lightweight and Interpretable Spiking Neural Model
Constitutional Law and AI Governance: Constraints on Model Licensing and Research Classification
Voice-Interactive Surgical Agent for Multimodal Patient Data Control
First, do NOHARM: towards clinically safe large language models
A Decision-Theoretic Approach for Managing Misalignment
aiXiv: A Next-Generation Open Access Ecosystem for Scientific Discovery Generated by AI Scientists
Systems pharmacology approaches decipher the anti-cancer efficacy of ethnopharmacological agents in hepatocellular carcinoma
Sci Rep. 2025 Dec 17;15(1):43996. doi: 10.1038/s41598-025-27744-w.
ABSTRACT
Hepatocellular carcinoma (HCC) poses a significant global health burden with limited therapeutic efficacy. Chinese herbal medicines (CHMs) offer multi-target potential, yet their systematic screening and mechanistic elucidation remain challenging. We established a high-throughput multi-omics platform integrating transcriptomics, proteomics, and deep learning (autoencoder and multiple kernel learning) to screen 187 medicinal plants. Five CHMs candidates were identified and shown to modulate hub genes (e.g., AKR1B10, HMGCR, THBS1) and key pathways (TNF/IL-17/MAPK, apoptosis, ferroptosis). Proteomic validation and functional assays confirmed their roles in suppressing proliferation, migration, and inducing apoptosis in HCC cells. This study provides a robust, data-driven pipeline for natural anti-HCC drug discovery, linking specific hub genes to CHM efficacy and offering novel insights into precision ethnopharmacology.
PMID:41408124 | DOI:10.1038/s41598-025-27744-w